Intranasal pharmaceutical compositions with improved pharmacokinetcs

The pharmaceutical formulation of claim 25, wherein the crystalline cellulose has a particle diameter range from about 5 to 250 μm.

The pharmaceutical formulation of claim 24, wherein the additional therapeutic agent is a salt of the additional therapeutic agent, a freebase of the additional therapeutic agent, or a mixture thereof.

An inhalable dry powder pharmaceutical formulation comprising a therapeutic agent wherein at least some of which is present in a freebase form, and wherein said formulation has a water-octanol Log D 7.4 of between about 0 and about 5.

An inhalable dry powder pharmaceutical formulation comprising a therapeutic agent wherein at least some of which is present in a freebase form, and wherein said formulation has a water-octanol Log P of between about 0 and about 5.

A pharmaceutical formulation comprising a therapeutic agent wherein at least some of therapeutic agent is present in a freebase form, and wherein following intranasal administration to a human, the taste profile is substantially less bitter or objectionable than the taste profile of an identical pharmaceutical formulation wherein the therapeutic agent is present as a salt form at the same molar quantity.

An inhalable dry powder pharmaceutical formulation comprising a therapeutic agent wherein at least some of the therapeutic agent is present in a freebase form, wherein the maximal blood therapeutic concentration (Cmax) of the therapeutic agent in the pharmaceutical formulation is at least 60% of the Cmax compared to the therapeutic agent when present at 100% salt form at the same molar quantity in an otherwise identical pharmaceutical formulation when administered to a primate.

An inhalable dry powder pharmaceutical formulation comprising a therapeutic agent wherein at least some of the therapeutic agent is present in a freebase form, wherein the time to reach a blood concentration of ½ of Cmax(T1/2) of to the therapeutic agent in the pharmaceutical formulation is at least 60% of the T1/2 compared to the therapeutic agent when present at 100% salt form at the same molar quantity in an otherwise identical pharmaceutical formulation when administered to a primate.

An inhalable dry powder pharmaceutical formulation comprising a therapeutic agent wherein at least some of therapeutic agent is present in a freebase form, wherein the time to reach a blood concentration Cmax (Tmax) of the therapeutic agent in the pharmaceutical formulation is at least 60% of the Tmax compared to the therapeutic agent when present at 100% salt form at the same molar quantity in an otherwise identical pharmaceutical formulation when administered to a primate.

An inhalable dry powder pharmaceutical formulation comprising a therapeutic agent wherein at least some of the therapeutic agent is present in a freebase form, wherein the bioavailability (BA) of the therapeutic agent in the pharmaceutical formulation is at least 60% of the BA compared to the therapeutic agent when present at 100% salt form at the same molar quantity in an otherwise identical pharmaceutical formulation when administered to a primate.

The pharmaceutical formulation of claim 74, wherein the formulation has a BA that at least 110% compared to the BA of the therapeutic agent when present at 100% salt form at the same molar quantity in an otherwise identical pharmaceutical formulation when administered to a primate.